New drug duo aims to boost immune attack on lung cancer
NCT ID NCT07507188
First seen Apr 05, 2026 · Last updated May 24, 2026 · Updated 11 times
Summary
This study tests two drug combinations for people with a specific type of advanced lung cancer (EGFR-mutant NSCLC). One group gets a new drug (amivantamab) plus a targeted pill (lazertinib) as their first treatment. Another group gets amivantamab plus chemotherapy after their cancer stopped responding to earlier targeted therapy. The main goal is to see how these combos affect the immune system inside tumors. About 80 adults will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
Explore the condition pages connected to this study.